Literature DB >> 19208825

Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1).

Wei Guo1, Shuhong Wu, Li Wang, Rui-yu Wang, Xiaoli Wei, Jinsong Liu, Bingliang Fang.   

Abstract

Protein kinase Ciota (PKCiota) is activated by oncogenic Ras proteins and is required for K-Ras-induced transformation and colonic carcinogenesis in vivo. However, the role of PKCiota in signal transduction and oncogenesis is not clear. We recently identified a small molecule, designated 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1), that can selectively kill K-Ras mutant cancer cells and induce abnormal nuclear aggregation of PKCiota in sensitive cells but not in resistant cells. To determine the causes and biological consequences of PKCiota aggregates in the nucleus, we analyzed the effect of oncrasin-1 on proteins involved in DNA repair and RNA processing. Our results showed that oncrasin-1 treatment led to coaggregation of PKCiota and splicing factors into megaspliceosomes but had no obvious effects on the DNA repair molecule Rad51. Moreover, oncrasin-1 treatment suppressed the phosphorylation of the largest subunit of RNA polymerase II and the expression of intronless reporter genes in sensitive cells but not in resistant cells, suggesting that suppression of RNA transcription is a major effect of oncrasin-1 treatment. Studies with cultured cells or with recombinant proteins showed that oncrasin-1 can disrupt the interaction of PKCiota and cyclin-dependent protein kinase 9/cyclin T1 complex, which is known to phosphorylate the largest subunit of RNA polymerase II and is required for RNA transcription. Together, our results suggest that oncrasin-1 suppresses the function of RNA processing machinery and that PKCiota might be involved in the biological function of RNA processing complexes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208825      PMCID: PMC2653085          DOI: 10.1158/1535-7163.MCT-08-0839

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  38 in total

Review 1.  Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C.

Authors:  Y Nishizuka
Journal:  Science       Date:  1992-10-23       Impact factor: 47.728

2.  Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1.

Authors:  J A Le Good; W H Ziegler; D B Parekh; D R Alessi; P Cohen; P J Parker
Journal:  Science       Date:  1998-09-25       Impact factor: 47.728

3.  Localisation of rapidly and slowly labelled nuclear RNA as visualized by high resolution autoradiography.

Authors:  S Fakan; W Bernhard
Journal:  Exp Cell Res       Date:  1971-07       Impact factor: 3.905

4.  Ultrastructural localization of transcription sites and of RNA distribution during the cell cycle of synchronized CHO cells.

Authors:  S Fakan; P Nobis
Journal:  Exp Cell Res       Date:  1978-05       Impact factor: 3.905

5.  Nucleolin is a protein kinase C-zeta substrate. Connection between cell surface signaling and nucleus in PC12 cells.

Authors:  G Zhou; M L Seibenhener; M W Wooten
Journal:  J Biol Chem       Date:  1997-12-05       Impact factor: 5.157

6.  Targeted deletion of protein kinase C lambda reveals a distribution of functions between the two atypical protein kinase C isoforms.

Authors:  Rachel S Soloff; Carol Katayama; Meei Yun Lin; James R Feramisco; Stephen M Hedrick
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

7.  Isolation of a complementary DNA that encodes the mammalian splicing factor SC35.

Authors:  X D Fu; T Maniatis
Journal:  Science       Date:  1992-04-24       Impact factor: 47.728

8.  A Ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: implications for cardiac hypertrophy.

Authors:  M Abdellatif; S E Packer; L H Michael; D Zhang; M J Charng; M D Schneider
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

9.  Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer.

Authors:  P Cornford; J Evans; A Dodson; K Parsons; A Woolfenden; J Neoptolemos; C S Foster
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

10.  Transcription-dependent colocalization of the U1, U2, U4/U6, and U5 snRNPs in coiled bodies.

Authors:  M Carmo-Fonseca; R Pepperkok; M T Carvalho; A I Lamond
Journal:  J Cell Biol       Date:  1992-04       Impact factor: 10.539

View more
  12 in total

Review 1.  Hedgehog pathway and GLI1 isoforms in human cancer.

Authors:  Richard L Carpenter; Hui-Wen Lo
Journal:  Discov Med       Date:  2012-02       Impact factor: 2.970

2.  Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells.

Authors:  Xiaoying Liu; Wei Guo; Shuhong Wu; Li Wang; Ji Wang; Bingbing Dai; Edward S Kim; John V Heymach; Michael Wang; Luc Girard; John Minna; Jack A Roth; Stephen G Swisher; Bingliang Fang
Journal:  Biochem Pharmacol       Date:  2012-02-22       Impact factor: 5.858

3.  Analogues and derivatives of oncrasin-1, a novel inhibitor of the C-terminal domain of RNA polymerase II and their antitumor activities.

Authors:  Shuhong Wu; Li Wang; Wei Guo; Xiaoying Liu; Jinsong Liu; Xiaoli Wei; Bingliang Fang
Journal:  J Med Chem       Date:  2011-04-06       Impact factor: 7.446

4.  Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380.

Authors:  Shuhong Wu; Li Wang; Xiao Huang; Mengru Cao; Jing Hu; Hongyu Li; Hui Zhang; Xiaoping Sun; Qing H Meng; Wayne L Hofstetter; Jack A Roth; Stephen G Swisher; Bingliang Fang
Journal:  Bioorg Med Chem       Date:  2014-08-14       Impact factor: 3.641

Review 5.  RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.

Authors:  Bingliang Fang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-09-07       Impact factor: 3.848

6.  Antagonistic effect of flavonoids on NSC-741909-mediated antitumor activity via scavenging of reactive oxygen species.

Authors:  Wei Guo; Xiaoli Wei; Shuhong Wu; Li Wang; Henry Peng; Ji Wang; Bingliang Fang
Journal:  Eur J Pharmacol       Date:  2010-09-18       Impact factor: 4.432

7.  Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition.

Authors:  Wei Guo; Shuhong Wu; Li Wang; Xiaoli Wei; Xiaoying Liu; Ji Wang; Zhimin Lu; Melinda Hollingshead; Bingliang Fang
Journal:  PLoS One       Date:  2011-12-12       Impact factor: 3.240

8.  Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380.

Authors:  Xiao Huang; Mengru Cao; Li Wang; Shuhong Wu; Xiaoying Liu; Hongyu Li; Hui Zhang; Rui-Yu Wang; Xiaoping Sun; Caimiao Wei; Keith A Baggerly; Jack A Roth; Michael Wang; Stephen G Swisher; Bingliang Fang
Journal:  Oncotarget       Date:  2015-01-01

Review 9.  Predictive biomarkers in precision medicine and drug development against lung cancer.

Authors:  Bingliang Fang; Reza J Mehran; John V Heymach; Stephen G Swisher
Journal:  Chin J Cancer       Date:  2015-07-02

10.  Genetic Interactions of STAT3 and Anticancer Drug Development.

Authors:  Bingliang Fang
Journal:  Cancers (Basel)       Date:  2014-03-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.